Ping An Securities News Today : Breaking News, Live Updates & Top Stories | Vimarsana

By Samuel Shen and Dhara Ranasinghe SHANGHAI/LONDON (Reuters) - Emboldened by China's latest measures and pledges to fix the weakest parts of its ...

Share prices have rebounded from multi-year lows in February on signs of more official support. The benchmark Shanghai index has climbed more than 3% since reports of the property rescue surfaced on Thursday, taking its gains to a fifth in 3-1/2 months, though the rally stalled on Tuesday as investors awaited more details on how the funding would work. Hong Kong-listed Chinese shares are up nearly 38%

China gave the green light to Eli Lilly & Co.'s blockbuster drug tirzepatide for use in treating diabetes, a move that will intensify the drugmaker's rivalry with Novo Nordisk A/S over weight-loss drugs in the world's second-largest market.

As China's economy shows signs of revitalisation, domestic investors eagerly embrace the nation's strategic moves.

Eli Lilly's diabetes drug tirzepatide receives approval in China, intensifying competition with Novo Nordisk's Ozempic. This move signals a significant expansion in the Asian market, where GLP-1 agonists are poised to drive a $2 billion market by 2030.